Stay updated on Efficacy of Nintedanib in COVID-19 Pulmonary Fibrosis Clinical Trial

Sign up to get notified when there's something new on the Efficacy of Nintedanib in COVID-19 Pulmonary Fibrosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efficacy of Nintedanib in COVID-19 Pulmonary Fibrosis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:22:22.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the estimated total number of cases for the study on the effectiveness and safety of Nintedanib in treating pulmonary fibrosis in patients with moderate to severe COVID-19.
    Difference
    0.1%
    Check dated 2024-06-06T14:20:35.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that participants must be 18-70 years old and confirmed to have a new coronavirus infection via throat swab nucleic acid test. Previously, no information was provided in this section.
    Difference
    17%
    Check dated 2024-05-22T20:30:41.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:15:29.000Z thumbnail image

Stay in the know with updates to Efficacy of Nintedanib in COVID-19 Pulmonary Fibrosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efficacy of Nintedanib in COVID-19 Pulmonary Fibrosis Clinical Trial page.